Why Simplist® - Simplist® Prefilled Syringes by Fresenius Kabi

Simplist reduces the amount of time nurses spend preparing doses and documenting waste¹

Simplist ready-to-administer prefilled syringes are there when you need to respond quickly in critical moments

Simplist syringes have differentiated labeling with bar codes, to help ensure the right medication, and the right dose

Simplified preparation helps reduce the opportunity for error²

Simplist ready-to-administer prefilled syringes are available in Blister and MicroVault^® packaging.

Learn more

Simplist is associated with a 4x lower error rate* compared to traditional practice, including a cartridge-based syringe system²

*A prospective, multisite, observational study of IV push medication preparation and administration compared the error rates between ready-to-administer products and traditional practice, including a cartridge-based syringe system and vial and syringe. Simplist was the only RTA delivery system used in the study. Study limitations include only a select number of sites (3) and steps observed.

Simplist ready-to-administer prefilled syringe by Fresenius Kabi

Ready-to-administer delivery system benefits¹

Medication Safety

Fewer steps and manipulations, minimizing contamination and limiting the opportunities for medication errors^1,3
Optimizing product presentations with single unit doses may reduce waste and financial burden⁴
Adherence to safety guidelines¹
Labeled and barcoded to help verification of proper drug and dose prior to administration, promoting safe medication delivery¹

Operational Efficiency

No dilution required
Time savings and improved workflow for nurses¹
Improved nurse satisfaction¹
Reduced training requirements for medication administration¹
Less variability in administration practices^1,3
Improved standardization^1,3

Ready-to-administer (RTA) medication systems are recommended by the Joint Commission,⁵ Institute for Safe Medication Practices (ISMP),³ American Society of Health-System Pharmacists (ASHP),⁶ and Anesthesia Patient Safety Foundation (APSF).⁷

We’re here to support best practices for your patients

We’re all working to respond to industry-wide challenges, to keep up with best practices, and adopt new regulations and guidelines. We’re doing our best to make change a little easier within the healthcare industry.

Optimization of product size may help reduce waste, saving time and additional resources required to document controlled substance disposal.

Read case study

“Limiting product waste and related documentation in the current environment is critical. Eliminating waste helps to streamline operations and free up staff time.“

Nathan Wooten, PharmD, Director of Pharmacy, United Regional Health Care System

Fentanyl Citrate Injection, USP

Please see complete Important Safety Information including Boxed Warning.

WARNING: RISK OF ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

See full Prescribing Information for complete Boxed Warning.

Important Safety Information

Fentanyl Citrate Injection

Indications and usage

Fentanyl Citrate Injection, for intravenous or intramuscular use, is indicated for:

Analgesic action of short duration during the anesthetic periods, premedication, induction and maintenance and in the immediate postoperative period (recovery room) as the need arises.
Use as an opioid analgesic supplement in general or regional anesthesia.
Administration with a neuroleptic as an anesthetic premedication, for the induction of anesthesia and as an adjunct in the maintenance of general and regional anesthesia.
Use as an anesthetic agent with oxygen in selected high risk patients, such as those undergoing open heart surgery or certain complicated neurological or orthopedic procedures.

Fentanyl Citrate Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

See full prescribing information for complete boxed warning.

Fentanyl Citrate Injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions
Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase.
Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl.
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.

Fentanyl Citrate Injection is contraindicated in patients with a hypersensitivity to fentanyl.

Risks of Skeletal Muscle Rigidity and Skeletal Muscle Movement: Manage with neuromuscular blocking agent. See full prescribing information for more detail on managing these risks.

Severe Cardiovascular Depression: Monitor during dosage initiation and titration.

Serotonin Syndrome: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue Fentanyl Citrate Injection if serotonin syndrome is suspected.

Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, or Head Injury: Monitor for sedation and respiratory depression.

The most common serious adverse reactions were respiratory depression, apnea, rigidity, and bradycardia.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Concomitant Use of CNS Depressants: May decrease pulmonary arterial pressure and may cause hypotension. See full prescribing information for management instructions. For post-operative pain, start with the lowest effective dosage and monitor for potentiation of CNS depressant effects.

Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Fentanyl Citrate Injection because they may reduce the analgesic effect of Fentanyl Citrate Injection or precipitate withdrawal symptoms.

Pregnancy: May cause fetal harm.

Lactation: Infants exposed to Fentanyl Citrate Injection through breast milk should be monitored for excess sedation and respiratory depression.

Geriatric Patients: Titrate slowly and monitor for CNS and respiratory depression.

This Important Safety Information does not include all the information needed to use FENTANYL CITRATE safely and effectively. Please see full prescribing information, including BOXED WARNING, for FENTANYL CITRATE INJECTION.

We’re here when you need us

Working with Fresenius Kabi’s support services can help optimize storage of Simplist prefilled syringes in medication automation systems and help assist clinicians in using best practices during Simplist medication administration. Click below to learn more.

Clinical Education

Storage Optimization

Simplified preparation helps reduce the opportunity for error2

Simplist is associated with a 4x lower error rate* compared to traditional practice, including a cartridge-based syringe system2

Ready-to-administer delivery system benefits1